enVVeno Medical's (NVNO) submission of the final module for VenoValve’s Premarket Approval (PMA) application to the FDA represents a crucial milestone in addressing unmet needs in the treatment of Chronic Venous Insufficiency (CVI). As a breakthrough-designated device, VenoValve aims to treat severe CVI by restoring proper blood flow and alleviating debilitating symptoms like leg swelling, pain, and venous ulcers.With approximately 2.5 million candidates for the device annually in the U.S., FDA approval cou ...